home / stock / ganx / ganx news

GANX News and Press, Gain Therapeutics Inc. From 03/21/23

Stock Information
Company Name: Gain Therapeutics Inc.
Stock Symbol: GANX
Market: NASDAQ
Website: gaintherapeutics.com
Menu
GANX GANX Quote GANX Short GANX News GANX Articles GANX Message Board
Get GANX Alerts

News, Short Squeeze, Breakout and More Instantly...
GANX - Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

BETHESDA, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced th...
GANX - Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and...

GANX - Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

BETHESDA, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and ...

GANX - Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences

BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and ...
GANX - Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and ...

GANX - Gain Therapeutics GAAP EPS of -$0.38 beats by $0.08

Gain Therapeutics press release ( NASDAQ: GANX ): Q3 GAAP EPS of -$0.38 beats by $0.08 . $25.7 Million in Cash and Cash Equivalents and Marketable Securities as of September 30, 2022 Provides Strong Financial Foundation and Extends Cash Runway into Q2 2024 For fu...

GANX - Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer and Appointed him to the Board of Directors...
GANX - Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek Medical Center GBA-Parkinson’s Disease Symposium BETHESDA, Md., Se...

GANX - Gain Therapeutics appoints CEO

Biotechnology company Gain Therapeutics ( NASDAQ: GANX ) said COO Matthias Alder has been appointed CEO, effective immediately. Alder, who was also appointed to the company's board, succeeds Eric Richman. The size of the company's board is now increased to eight m...

GANX - Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sit...
Previous 10 Next 10